目的 分析遼寧省腫瘤醫(yī)院2020—2022年免疫檢查點(diǎn)抑制劑的使用情況以及變化趨勢，為規(guī)范其管理及臨床合理使用提供參考。方法 收集2020—2022年遼寧省腫瘤醫(yī)院免疫檢查點(diǎn)抑制劑使用數(shù)據(jù)，分析銷售金額、用藥頻度（DDDs）、限定日費(fèi)用（DDC）以及排序比（B/A）。結(jié)果 2020—2022年免疫檢查點(diǎn)抑制劑銷售金額大幅增長。帕博利珠單抗和替雷利珠單抗使用金額較大，排名靠前。2022年新增的品種（阿替利珠單抗、卡度尼利單抗、賽帕利單抗、斯魯利單抗、舒格利單抗、恩沃利單抗）銷售金額排名靠后。替雷利珠單抗的DDDs近3年大幅增加?？ǘ饶崂麊慰埂⒍确ダ葐慰?、帕博利珠單抗、納武利尤單抗DDC值偏高，且B/A＜1。信迪利單抗、替雷利珠單抗、卡瑞利珠單抗、特瑞普利單抗DDC在2022年有大幅度的下降，DDC值較低，且B/A＞1。結(jié)論 2020—2022年遼寧省腫瘤醫(yī)院免疫檢查點(diǎn)抑制劑的使用總體上比較合理，但仍需進(jìn)一步加強(qiáng)監(jiān)管力度，保障患者用藥的安全、有效和經(jīng)濟(jì)。

Objective To analyze the usage and variation tendency of immune checkpoint inhibitors in Liaoning Cancer Hospital and Institute from 2020 to 2022, and provide references for standardizing the management and rational application. Methods Consumption sum, defined daily doses (DDDs), defined daily cost (DDC), and drug sequence ratio of immune checkpoint inhibitors in Liaoning Cancer Hospital and Institute from 2020 to 2022 were analyzed statistically. Results Consumption sum and constituent ratio increased sharply year by year. Consumption sums of pembrolizumab and tislelizumab increased year by year. In 2022, consumption sums of new varieties (atezolizumab, cadonilimab, zimberelimab, serplulimab, sugemalimab, envafolimab) ranked lower. The DDDs of tislelizumab increased significantly for three consecutive years. The DDC values of cadonilimab, durvalumab, pembrolizumab and nivolumab are high, and B/A < 1. The DDC of sintilimab, toripalimab, camrelizumab, and tislelizumab decreased significantly in 2022, with a low DDC value and B/A > 1. Conclusion From 2020 to 2022, the use of immune checkpoint inhibitors in Liaoning Cancer Hospital and Institute is generally reasonable. However, it is still necessary to further strengthen supervision to ensure the safety, effectiveness and economy of treatment drugs.

R979.1

遼寧省腫瘤醫(yī)院質(zhì)譜課題項(xiàng)目（ZP202019）